Adalimumab

證據等級: L5

預測適應症: 6 個

Adalimumab: From Rheumatoid Arthritis to Rheumatoid Vasculitis

One-Sentence Summary

Adalimumab is a fully human anti-TNF-α monoclonal antibody approved globally for rheumatoid arthritis and related inflammatory diseases, though no regulatory records were returned from the queried database for this report. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, with 5 clinical trials and 20 publications currently supporting this direction. The most significant supporting evidence is a 2021 systematic review (PMID 33058033) that specifically evaluated biological therapies—including adalimumab—in rheumatoid vasculitis, anchoring this prediction at an L3 evidence level.

Quick Overview

Item	Content
Original Indication	No records in queried database (adalimumab is globally known for rheumatoid arthritis and related inflammatory diseases)
Predicted New Indication	Rheumatoid Vasculitis
TxGNN Prediction Score	99.80%
Evidence Level	L3
US Market Status	Not found in regulatory database
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data was not returned by the database query. Based on known information, adalimumab is a fully human IgG1 monoclonal antibody that selectively binds and neutralizes both the soluble and membrane-bound forms of TNF-α. By blocking TNF-α, adalimumab interrupts downstream inflammatory cascades—reducing interleukin-1 and IL-6 production, metalloproteinase activity, and endothelial adhesion molecule expression—that drive joint destruction and systemic inflammation in autoimmune disease.

Rheumatoid vasculitis (RV) is one of the most severe extra-articular complications of long-standing rheumatoid arthritis, characterized by immune complex deposition and inflammatory infiltration of small-to-medium blood vessels. Because both RA synovitis and RV share the same upstream TNF-α-mediated inflammatory pathway, applying adalimumab to RV carries clear biological plausibility. A 2021 systematic review (PMID 33058033) confirmed that biological agents—including anti-TNF therapies—are now incorporated into the therapeutic armamentarium for refractory RV. The case reported in PMID 30773522 further illustrates this relationship: an acute pulmonary hypertension crisis emerged eight months after adalimumab dose reduction in an RV patient, underscoring the drug’s active role in maintaining vascular disease control.

However, the picture is not entirely straightforward. A large pharmacoepidemiological study from the BSRBR-RA registry (PMID 28123776) and multiple case reports document that TNF-α inhibitors may paradoxically trigger or worsen vasculitis-like events in certain RA patients. This dual role—simultaneously treating and potentially inducing vasculitis—introduces a meaningful safety uncertainty that must be resolved before clinical advancement can be recommended.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05696106	N/A	Unknown	750,000	Large observational study tracking the incidence of IMIDs (including vasculitis) in patients treated with biologics and immunosuppressants; provides safety and baseline incidence context for biologic-associated vasculitis risk
NCT02590562	N/A	Completed	808	Cross-sectional study of biologic DMARD treatment patterns in Chinese RA patients; provides background on adalimumab use in routine RA practice
NCT01579006	N/A	Completed	184	Observational study of tocilizumab in RA patients with inadequate response to prior biologics; provides real-world safety comparison data for RA biologic therapy
NCT07138898	Phase 2	Not Yet Recruiting	80	Perioperative immunosuppressant management in rheumatology patients undergoing elective shoulder arthroplasty; provides guidance on surgical risk management in immunosuppressed patients
NCT05111743	N/A	Completed	9,261	Retrospective cohort study of brolucizumab for wet AMD; drug and disease are unrelated to rheumatoid vasculitis, included only as retrieved evidence

Note: No clinical trials specifically designed to evaluate adalimumab for rheumatoid vasculitis were identified. The trials above provide only indirect background and safety context.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33058033	2021	Systematic Review	Clinical Rheumatology	PRISMA-based systematic review of biological therapies in RV; confirms anti-TNF agents (including adalimumab) are used clinically, given RV’s significant morbidity and mortality
18799049	2008	Systematic Review	Clin Exp Rheumatology	Analyzed 18 vasculitis cases from 2,707 RA patients; compared characteristics of vasculitis occurring during anti-TNF treatment versus without
28123776	2017	Pharmacoepidemiology	RMD Open	BSRBR-RA registry study quantifying drug-specific risk of lupus-like and vasculitis-like events in TNFi-treated RA; key safety signal for paradoxical vasculitis induction
25133007	2014	Case Report	Case Reports in Rheumatology	15-year RA patient with digital vasculitis and fingertip necrosis responded well to adalimumab; direct evidence of efficacy in RA-associated vascular involvement
30773522	2019	Case Report	Internal Medicine (Tokyo)	Acute pulmonary hypertension crisis emerged 8 months after adalimumab dose reduction in a confirmed RV patient, highlighting the drug’s importance in maintaining vascular disease control
34068884	2021	Review	J Clinical Medicine	Update on RA-associated episcleritis and scleritis; discusses adalimumab and other biologics for ocular vasculitis manifestations in RA patients
28719435	2018	Case Report	Am J Dermatopathology	First reported case of leukocytoclastic vasculitis with cutaneous perivascular hemophagocytosis in an RA patient after initiating adalimumab; illustrates paradoxical vasculitis risk
36418100	2023	Case Report	Internal Medicine (Tokyo)	ANCA-associated nephritis emerging during abatacept + adalimumab combination therapy for RA; tocilizumab resolved the renal vasculitis, informing treatment sequencing
19482531	2009	Case Report	Néphrologie & Thérapeutique	MPO-ANCA-positive extracapillary necrotizing glomerulonephritis arising in RA patient treated with adalimumab; highlights renal vasculitis as a potential adverse effect
23559388	2013	Case Report	Clinical Rheumatology	First reported adalimumab-associated antiphospholipid syndrome; includes a literature review of adalimumab-induced vasculitis and APS cases

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: While the biological plausibility for using adalimumab in rheumatoid vasculitis is supported by shared TNF-α-driven pathology and a dedicated systematic review, the current evidence base (L3) contains no Phase 2/3 RCT designed specifically for this indication. Critically, paradoxical TNFi-induced vasculitis-like events documented across multiple sources introduce a safety uncertainty that must be characterized before clinical advancement is responsible.

To proceed, the following is needed:

Establish a prospective observational registry enrolling RA patients with confirmed rheumatoid vasculitis to collect structured adalimumab response data (response rate, time to improvement, relapse on dose reduction)
Resolve the therapeutic paradox: define clinical, serological, or genetic biomarkers that distinguish patients likely to benefit from adalimumab versus those at risk for TNFi-induced vasculitis exacerbation (refer to PMID 28123776, 28719435, 19482531)
Retrieve complete FDA regulatory records, package insert warnings, contraindications, and known drug interactions for adalimumab (all unavailable in this evidence pack and classified as data gaps)
Conduct a full extraction of the 2021 systematic review (PMID 33058033) to enumerate patient-level response data and inform a prospective pilot trial design
Commission a safety sub-analysis specifically on ANCA-associated vasculitis events during adalimumab therapy (PMIDs 36418100, 19482531) to quantify the renal risk signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.